登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市肺科医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07410975,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC).
入选标准第 3 条
No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy. Traditional Chinese medicine given for anticancer intent is permitted provided it was discontinued ≥ 2 weeks before first dose.
入选标准第 4 条
Major thoracic or abdominal surgery within 28 days before first dose or incomplete recovery from previous surgery.
排除标准第 1 条
ECOG performance status 0 or 1.
入选标准第 8 条
Haemoglobin ≥ 90 g/L (no transfusion within 28 days)
入选标准第 10 条
Absolute neutrophil count ≥ 1.5 × 10⁹/L
入选标准第 11 条
Platelet count ≥ 100 × 10⁹/L (no platelet transfusion or IL-11 within 14 days)
入选标准第 12 条
Creatinine clearance ≥ 60 mL/min (Cockcroft-Gault)
入选标准第 13 条
Total bilirubin ≤ 1.5 × ULN (≤ 2.5 × ULN in Gilbert's syndrome or hepatic metastases)
入选标准第 14 条
ALT and AST ≤ 3 × ULN
入选标准第 15 条
INR or aPTT ≤ 1.5 × ULN
入选标准第 16 条
Active hepatitis B (HBsAg positive and HBV DNA > 500 IU/mL or > 2000 copies/mL) or hepatitis C (HCV antibody and HCV RNA positive). Subjects with HBV DNA ≤ 500 IU/mL who agree to antiviral prophylaxis are eligible.
排除标准第 8 条
Known HIV infection or history of AIDS.
排除标准第 9 条
Fertile female must have a negative serum pregnancy test within 7 days before first dose.
入选标准第 18 条
Fertile female and male patients with female partners of childbearing potential must use a highly effective contraceptive method (annual failure rate < 1 %) from 7 days before first dose until 24 weeks after the last dose.
入选标准第 19 条
Pregnancy or lactation.
排除标准第 16 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07410975,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
The patient shall sign the informed consent. Age ≥ 18 years. Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC). No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy. Traditional Chinese medicine given for anticancer intent is permitted provided it was discontinued ≥ 2 weeks before first dose. Investigator-assessed resectable Stage II-IIIB (N3 excluded) NSCLC per AJCC 9th. Non-squamous NSCLC: no EGFR mutation, ALK rearrangement or any other driver mutation with an approved targeted agent. Squamous NSCLC: no known EGFR mutation, ALK rearrangement or other actionable driver mutation. PD-L1 expression negative (22C3 or E1L3N). ECOG performance status 0 or 1. Adequate organ function within 7 days before first dose: Haemoglobin ≥ 90 g/L (no transfusion within 28 days) Absolute neutrophil count ≥ 1.5 × 10⁹/L Platelet count ≥ 100 × 10⁹/L (no platelet transfusion or IL-11 within 14 days) Creatinine clearance ≥ 60 mL/min (Cockcroft-Gault) Total bilirubin ≤ 1.5 × ULN (≤ 2.5 × ULN in Gilbert's syndrome or hepatic metastases) ALT and AST ≤ 3 × ULN INR or aPTT ≤ 1.5 × ULN FEV> 2L, FEV1> 1L, FEV1/FVC ≥ 70%, DLCO ≥ 70% predicted; or Investigator determination that pulmonary reserve is adequate for planned surgery. Fertile female must have a negative serum pregnancy test within 7 days before first dose. Fertile female and male patients with female partners of childbearing potential must use a highly effective contraceptive method (annual failure rate < 1 %) from 7 days before first dose until 24 weeks after the last dose.排除标准:Exclusion Criteria:
Major thoracic or abdominal surgery within 28 days before first dose or incomplete recovery from previous surgery. Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/day) or other immunosuppressive agents for ≥ 7 consecutive days within 14 days before first dose. Except for inhaled or topical corticosteroids, or corticosteroid therapy at physiological replacement doses for adrenal insufficiency; short- courses (<7 days) corticosteroid use is permitted for the prevention or treatment of non-autoimmune conditions; Participants who received live vaccines (including live attenuated vaccines) within 28 days before first dose. Current or prior interstitial pneumonia or pulmonary diseases requiring systemic glucocorticoids. Presence of any active autoimmune disease or history of autoimmune disease. Except in the following cases: Type 1 diabetes, stable hypothyroidism under hormone replacement therapy, psoriasis or vitiligo not requiring systemic treatment. Other malignancy within 5 years before first dose, except for tumors assessed by the investigator as cured. Uncontrolled comorbidities, including: Active hepatitis B (HBsAg positive and HBV DNA > 500 IU/mL or > 2000 copies/mL) or hepatitis C (HCV antibody and HCV RNA positive). Subjects with HBV DNA ≤ 500 IU/mL who agree to antiviral prophylaxis are eligible. Known HIV infection or history of AIDS. Active tuberculosis. Active infection requiring systemic antibiotics for > 7 days within 28 days before first dose. Clinically significant cardiovascular disease: cerebrovascular accident within 6 months, symptomatic heart failure (NYHA class II-IV), unstable angina or myocardial infarction within 6 months, risk of QTc prolongation or arrhythmia. Urine protein qualitative≥ 2+, and 24-hour urine protein test > 1g History of allogeneic haematopoietic stem-cell or solid-organ transplantation. Hypersensitivity to antibody therapies (≥ grade 3 NCI-CTCAE v6.0), history of anaphylaxis, uncontrolled asthma, or significant drug allergies. Pregnancy or lactation. Other conditions that may affect the safety or compliance of drug therapy in this study include, but are not limited to, psychiatric disorders, uncontrolled large serosal cavity effusions, or moderate to large serosal cavity effusions requiring repeated drainage (recurring within 2 weeks after intervention), such as pleural effusion, pericardial effusion, or ascites cachexia.
引自 ClinicalTrials.gov, NCT07410975, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07410975,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。